Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany

OBJECTIVE: To assess the long-term real-world benefit–risk profile of fingolimod in patients with relapsing MS in Germany. METHODS: This analysis used data from the noninterventional real-world study, Post-Authorization Non-interventional German sAfety study of GilEnyA (PANGAEA), to assess prospecti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Neuroimmunol Neuroinflamm
Main Authors: Ziemssen, Tjalf, Lang, Michael, Tackenberg, Björn, Schmidt, Stephan, Albrecht, Holger, Klotz, Luisa, Haas, Judith, Lassek, Christoph, Couto, C. Anne-Marie, Findlay, John A., Cornelissen, Christian
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6410931/
https://ncbi.nlm.nih.gov/pubmed/30882022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000548
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados